MANKIND PHARMA
|
The Current P/E Ratio of MANKIND PHARMA is 46.34.
| Share Price | ₹2,305.9 | Sep 08,2026 |
| Market Cap | ₹95,231.6 Cr | |
| Earnings-TTM | ₹2,055.1 Cr | TTM-Consolidated Results |
| Price/Earnings | 46.34x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MANKIND PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹95,231.6 Cr] as on Sep 08,2026
(/) Earnings [ ₹2,055.1 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 46.34x ]
Thus, for MANKIND PHARMA , the investors are currently willing to pay 46.34 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MANKIND PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MANKIND PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MANKIND PHARMA
PE Ratio Performance Analysis for MANKIND PHARMA
- MANKIND PHARMA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 28.32x.
- MANKIND PHARMA 's operated at median p/e ratio of 43.29x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MANKIND PHARMA 's p/e ratio peaked in Mar2025 at 50.22x.
- MANKIND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does MANKIND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MANKIND PHARMA | 2,055.11 | 46.34 | 95,231.6 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.08 | 451,339.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 86.86 | 254,068.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 87.55 | 188,767.0 |
| CIPLA LTD | 3,364.84 | 33.23 | 111,804.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 30.33 | 96,113.4 |
| LUPIN LTD | 5,551.01 | 17.40 | 96,574.5 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.54 | 114,713.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 26.13 | 97,008.7 |
| LAURUS LABS LTD | 1,090.76 | 96.37 | 105,118.0 |
| BIOCON LTD | 416.40 | 153.63 | 63,973.6 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MANKIND PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.40x |
| Max industry PE | 153.63x |
| Median industry PE | 37.08x |
| Average industry PE | 58.22x |
You may also like the below Video Courses